IMPORTANCE Optimal use of whole-exome sequencing (WES) in the pediatric setting requires an understanding of who should be considered for testing and when it should be performed to maximize clinical utility and cost-effectiveness.
C hildren affected by genetic conditions often have multisystem disease, experience substantial morbidity and mortality, and have higher hospitalization rates with longer admissions compared with the general pediatric population. [1] [2] [3] The evaluation for a genetic condition in a child, the so-called diagnostic odyssey, typically involves clinical assessment and multiple investigations, many of which are invasive and costly. The diagnostic trajectory can be prolonged, and many children continue to have undiagnosed conditions. Each technological advance in genetic analysis offers an opportunity to improve diagnostic yield, as exemplified by chromosomal microarray over conventional karyotyping, 4 but none has the diagnostic power of genomic sequencing. Whole-exome sequencing (WES), the analysis of the protein-coding exons of genes, has the potential to revolutionize the diagnosis in children suspected of having monogenic disorders. 5, 6 Large-scale studies [7] [8] [9] [10] [11] [12] [13] of WES in children with broad clinical presentations report diagnostic rates of 25% to 30%, applying WES after multiple genetic investigations, including single-gene or panel testing. Studies using WES as a last resort result in ascertainment bias toward diagnostically difficult cases because children with conditions diagnosed with an earlier gene test would be excluded. The application of WES to a clinically ascertained, sequencing-naive cohort is needed to understand the full impact of WES in the pediatric clinic and to assist clinicians in knowing when and for whom to consider singleton WES. Few studies have investigated the cost-effectiveness of WES in the clinical setting, although an evaluation 14 of the standard diagnostic approach hypothesized that applying nextgeneration sequencing at the first clinical visit could result in considerable cost savings. A study 13 of syndromic children, more than half of whom had undergone single-gene or multigene panels, evaluated the cost-effectiveness of WES, but this was limited to comparing the cost of WES with the cost of prior genetic testing without including other diagnostic investigations. An evaluation 15 of the retrospective use of trio WES in a cohort of 17 children with intellectual disability found that it would have been less costly than the traditional diagnostic trajectory. Although this study indicated that WES would have been less costly than other investigations, retrospective studies do not include those who receive a diagnosis through usual diagnostic care; thus, the applicability of those studies to clinical practice is limited. When undertaking a robust study of the cost-effectiveness of WES, it is important to undertake WES prospectively in a clinical cohort and to include all investigations for diagnostic purposes, such as brain magnetic resonance imaging and metabolic investigations, because it is feasible that with early WES diagnosis, these tests may no longer be necessary. A previous prospective study 16 focused on infants younger than 2 years who were suspected of having a monogenic disorder and found a diagnostic yield of 57% for WES compared with 13.5% diagnosed with standard care. In the present study, we sought to prospectively determine the diagnostic yield of WES in older, ambulant children suspected of having a monogenic condition but who were sequencing naive, that is, having not had any single-gene or panel testing. We assessed the cost-effectiveness of the use of WES at the start of the diagnostic odyssey, first presentation to a clinical geneticist, and at the end of the standard diagnostic pathway in a clinical cohort, capturing the impact of the inclusion of WES on the cost of all investigations undertaken for diagnostic purposes in the hospital setting. Our objectives were to determine the clinical impact of WES in these children and to determine the point in the diagnostic trajectory at which WES is most costeffective.
Methods

Study Design and Participants
We prospectively recruited ambulant children aged 2 to 18 years suspected of having a monogenic condition from the outpatient clinics of Victorian Clinical Genetics Services at the Royal Children's Hospital, Melbourne, Australia, from May 1 through November 30, 2015. The Royal Children's Hospital is the major tertiary referral center for children in the states of Victoria and Tasmania. All children had at least one clinical assessment by a clinical geneticist, and a panel of investigators discussed each case to determine eligibility. Our study population represents a typical cohort referred by pediatricians for genetics evaluation but remaining undiagnosed after clinical assessment. We did not include children whose diagnosis would usually be made by clinical assessment, such as achondroplasia or neurofibromatosis type 1. All children in our cohort had a nondiagnostic single-nucleotide polymorphism microarray. We included only children who had not had any prior 
Costing Approach
We collected cost data in Australian dollars for all children 22 from dates that included initial presentation to tertiary services for diagnostic purposes, first clinical genetics assessment, enrollment, and WES report. All diagnostic inpatient and outpatient episodes of care, including investigations, specialists consulted, duration of admission, and travel, were collected from medical records. We obtained costs of hospital admissions, outpatient specialist appointments, case conferences, diagnostic investigations (including operating theater and general anesthesia from the Clinical Costings Department of the Royal Children's Hospital), and the Australian Medicare Benefits Schedule (http://www.mbsonline.gov.au). We estimated the shortest distance from home to the Royal Children's Hospital multiplied by the cost per kilometer (A$0.20 [US$0 .15] as per the Victorian Patient Assistance Scheme; https: //www2.health.vic.gov.au/hospitals-and-health-services /rural-health/vptas-how-to-apply) to calculate the costs incurred by the health system for travel from home, for which the family is reimbursed by the state. We obtained costs of any flights required from the most economical carrier.
Cost-effectiveness Analysis
We considered 3 diagnostic counterfactual scenarios 23 and the actual trajectory and compared their costs and diagnostic yields to investigate which option was most cost-effective ( Figure 1 ). First, we considered the standard diagnostic pathway without WES, which included all investigations and clinical assessments that occurred primarily for diagnostic purposes, including microarray, without costs associated with WES. Second, we considered the standard diagnostic pathway with WES, which included all aforementioned investigations and clinical assessments with WES as the final test. The cost of singleton WES was provided by the laboratory service, and the genetic service delivery model included consultations with a clinical geneticist and genetic counselor for pretest assessment or counseling and result disclosure. We included the cost of proband and parental Sanger sequencing to validate variants detected by WES. Third, we considered WES at the first genetics appointment, which included all costs up to and including the first genetics appointment with cost of WES (test, Sanger validation, and genetic service delivery) incorporated. Fourth, we considered WES at initial tertiary presentation, which included all costs incurred leading to the initial appointment at a tertiary hospital, with the cost of WES (test, Sanger validation, and genetic service delivery) replacing the initial tertiary assessment and investigations.
Sensitivity Analysis
We undertook sensitivity analysis using a higher cost of singleton WES in another Australian laboratory (A$2300) to examine robustness of the original estimates.
Statistical Analysis
We calculated mean cost per patient, mean cost per diagnosis, and incremental cost per additional diagnosis for WES used at 3 time points in the diagnostic pathway compared with the standard diagnostic trajectory. We performed bootstrap simulations with 1000 replications to determine 95% CIs of all outcomes to examine the distribution of our estimates. 24 All statistical analyses were performed in Microsoft Excel (Microsoft Corp) and SAS statistical software, version 9.4 (SAS Institute Inc).
Results
Of 61 children initially assessed, 17 were excluded (novel phenotype, n = 3; enrolled in another genomic project, n = 7; declined or consent withdrawn, n = 5; microarray diagnosis, n = 2), leaving 44 children aged 2 to 18 years who were prospectively recruited from outpatient clinics ( Table 1) . There were 21 male children (48%) and 23 female children (52% The mean age at initial presentation to tertiary services for diagnostic purposes was 28 months (range, 0-121 months). The mean interval between first presentation to tertiary services and genetics assessment was 13 months (range, 0-113 months). Two children had antenatal ultrasound anomalies detected, and their first postnatal contact with tertiary services was pediatric and genetics assessments at birth. The mean duration from consent to WES report was 181 days (range, 40-283 days). Most children (37 of 44 [84%]) were referred by general or subspecialist pediatricians, and all had nondiagnostic chromosomal microarray. All children with developmental or intellectual disability underwent testing for fragile X syndrome. In addition to a clinical geneticist, the mean number of specialists seen by each child for diagnostic purposes was 4 (range, 1-7). Twenty-six children (59%) required general anesthesia for diagnostic purposes. Nine children were admitted to the hospital for diagnostic workup; one child required 2 admissions.
Whole-exome sequencing achieved a molecular diagnosis in 23 of 44 children (52%) (eTable in the Supplement). In 8 children (35%) with diagnosed conditions, the causative gene was clinically unexpected and not in the prioritized gene list. Most of the diagnoses were de novo heterozygous mutations (14 of 23 [61%]), followed by autosomal recessive (6 of 23 Age at presentation to tertiary care for diagnostic purposes, mean (range), mo Stopping planned investigations 1 (2)
Prenatal diagnosis 1 (2)
Abbreviation: WES, whole-exome sequencing.
a Data are presented as number (percentage) of children unless otherwise indicated.
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[26%]), X-linked recessive (2 of 23 [9%]), and autosomal dominant (1 of 23 [4%]; affected mother) conditions. Of the 23 children with diagnosed conditions, clinical management was altered in 6 (26%), whereas 1 had additional diagnostic investigations canceled and the parents of 1 had prenatal and preimplantation genetic diagnosis planned. The total health care expenditure including WES in this cohort was A$568 141 (US$430 873). We examined the bootstrapped cost per patient following 4 diagnostic trajectories: standard pathway without WES, standard pathway with WES, WES performed at initial tertiary presentation, and WES performed at first genetics appointment ( Table 2 (Figure 2 ) for this cohort confirms that WES performed at initial tertiary presentation was most cost-effective compared with the standard diagnostic pathway. The bootstrapped analyses indicate that these results can be extrapolated to a larger cohort.
Discussion
Our study confirms the clinical utility of WES in syndromic children and provides strong evidence to support its use early in the diagnostic trajectory. The children prospectively recruited for singleton WES were suspected of having a genetically heterogeneous condition or had features overlapping several conditions. We excluded children with novel phenotypes more suited to gene discovery projects and those with highly specific features more appropriately investigated with single-gene tests. In subgroup analysis, we found that the lowest diagnostic yield (14%) was in those with intellectual disability without congenital anomalies. Trio WES may have a higher yield in this subgroup. 25, 26 The higher diagnostic yield (86%) in those suspected of having a genetically heterogeneous condition compared with those with an unknown diagnosis (39%) suggests that the former represents a more genetically tractable group, which is consistent with the relatively high yields of targeted panels for specific phenotypes. 27,28 A targeted panel with multiplex ligation-dependent probe amplification instead of WES in those with a genetically heterogeneous condition may have resulted in a higher diagnostic yield because of better coverage and discovery of indels, with different cost implications. However, WES affords a more comprehensive approach to genetically heterogeneous conditions, allowing reanalysis of new genes and analysis of the Mendeliome, and is likely to be more cost-effective than gene-by-gene interrogation.
9
We expected that the diagnostic yield in our cohort of ambulant children would be lower than that observed in a previous study of infants 16 because we were ascertaining older children who remained undiagnosed beyond infancy. The observation that the diagnostic yield was equivalent (52%) probably reflects the similar approach in both studies, with prospective ascertainment, thorough phenotyping, defined selection criteria, and close clinician-laboratory partnership in the use of phenotype knowledge for variant curation. Sustainable solutions to integrate clinician input into variant curation remain an important challenge if the true power of WES is to be realized. Although phenotyping is critical, 35% of children had a diagnosis caused by a gene outside the initially prioritized gene list. This finding not only possibly reflects lack of clinical recognition but also underscores the utility of WES in achieving a diagnosis even when the a priori hypothesis is imprecise.
In our study, WES demonstrated benefits beyond resolution of the diagnostic odyssey, leading to clinically meaningful outcomes, such as a change in management in 6 of 23 cases (26%), stopping of planned investigations, and prenatal or preimplantation genetic diagnosis in another 2 of 23 cases (9%). Management changes included the institution of surveillance for complications, stopping of surveillance for suspected diagnoses when an alternative diagnosis was confirmed, and referral for specialist assessment of known or evolving complications of the condition. This finding is similar to what we observed with the infant cohort and reported by others.
9,13,16
We documented the diagnostic trajectory of the children in our cohort and modeled the cost-effectiveness of WES applied at different time points. We found that the cost of the standard diagnostic pathway was high and that earlier application of WES maximized cost-effectiveness. This cohort is distinct from the neonates and infants previously described 16,29,30 because they were less acutely unwell and had a higher mean age of 28 months at first presentation. The phenotypic subgroup of intellectual disability without congenital anomalies would be unusual in an infant cohort. Our study also differs from others reporting clinical utility of WES 8,10-14,31,32 because we recruited children in whom In a retrospective cohort of children with neurodevelopmental disorders, the diagnostic yield was 40% in the ambulatory subgroup and retrospective evaluation suggested that the break-even point at which trio WES would cost no more than standard diagnostic investigations (excluding physician appointments) would be US$7640 per family (US$2996 for singleton WES). 31 A retrospective study 15 of 17 children with intellectual disability with previously undiagnosed conditions found that WES delivered substantial cost savings if other genetic tests and metabolic investigations were replaced. Although we found that WES is most cost-effective early in the diagnostic trajectory, WES is not to replace a thorough clinical geneticist evaluation. Accordingly, we incorporated the costs of genetics appointments in all scenarios that involve WES. We suggest that early referral of a syndromic child by their pediatrician to a clinical geneticist be considered; however, rather than being offered to all referred children, singleton WES has highest clinical utility in selected children in whom a phenotype-driven gene list can be generated. Although trio WES may have further improved the diagnostic yield in those with nonsyndromic intellectual disability, its cost-effectiveness needs to be determined. A similar evaluation would need to be undertaken to determine the clinical utility and costeffectiveness of whole-genome sequencing.
Limitations
As mentioned, this study has several limitations. Our patient group comprises children with genetically heterogeneous conditions or features that overlap several conditions rather than all referred children. Other limitations include the sustainability of our WES service delivery model and conservative cost estimates. In addition, future studies that randomize children to different pathways of WES application are needed.
Conclusions
The diagnostic odyssey of children suspected of having monogenic disorders is protracted and painful and may not provide a precise diagnosis. This paradigm has markedly shifted with the advent of WES. Our prospective study provides compelling evidence for the clinical utility and costeffectiveness of WES at an early point in the diagnostic trajectory. The children in whom WES is likely to have the highest diagnostic yield are those with genetically heterogeneous disorders or features overlapping several conditions. Wholeexome sequencing has additional benefits of helping in diagnoses when the initial clinical hypothesis is imprecise and allows future data reanalysis in children whose conditions remain undiagnosed. Our findings suggest that these children are best served by early recognition by their pediatrician and expedited referral to clinical genetics with WES applied after chromosomal microarray but before an extensive diagnostic process. 
